Abstract. The aim of this study was to determine the role of curative resection in metastatic colorectal cancer (CRC) and determine the subset of patients who may benefit from concurrent curative resection of primary and metastatic lesions. A total of 103 patients diagnosed with synchronous liver and/or lung metastatic CRC at the Osaka Medical Center for Cancer and Cardiovascular Diseases between 1983 and 2010 were retrospectively investigated. All the patients underwent curative resection of the primary and metastatic lesions. The median follow-up time was 5.69 years. A total of 83 and 13 patients had only liver or lung metastasis, respectively, whereas 7 patients had synchronous liver and lung metastases. A total of 25 patients (24.2%) had no recurrence following curative resection and 14 patients (13.5%) received more than one re-resection for disease recurrence and survived without any further recurrence thereafter. The 5-year survival of liver or lung metastatic CRC was 43.7 or 90.0%, respectively. However, the median overall survival (OS) in patients with synchronous liver and lung metastases was 20.7 months. In the univariate and multivariate analyses, tumour invasion, synchronous liver and lung metastases and time-to-recurrence after the first curative resection were significantly associated with OS and disease-free survival. In conclusion, curative resection confers longer-term survival in patients with liver or lung metastatic CRC.
Introduction
In developed countries, where the aging population is on the increase, cancer is a major health concern, in terms of public welfare and preventive measures, with a cancer-related to overall mortality ratio of 1:4 in the United States (1) . Colorectal cancer (CRC) is one of the most common malignancies and among the leading causes of cancer-related mortality. Approximately 1 in 5 patients with CRC present with distant metastatic disease at diagnosis and the distant metastases, such as to the liver or lung, are the major cause of death. A significant proportion of patients with metastatic CRC are not curable; however, a subset of these patients with liver-and/or lung-isolated disease is potentially curable with surgery (2) (3) (4) .
When treating metastatic CRC, systemic chemotherapy is the standard approach. Over the last decade, there has been significant progress in CRC treatment strategies. Compared to the era when 5-fluorouracil (5-FU) was the only efficient drug against CRC, the median survival duration has increased over the last few years, mainly due to the availability of novel agents, such as irinotecan and oxaliplatin, along with cetuximab and bevacizumab (5) (6) (7) . Although several new drugs are currently used for metastatic CRC, it is difficult to change the standard treatment with surgical resection.
The role of synchronous curative resection for CRC with lung and/or liver metastases is limited. Previous studies on these treatments were retrospective and included small sample sizes with short-term follow-up periods (3, 4) . Therefore, it is difficult to determine the benefits of curative resection for primary and metastatic lesions concurrently. In this study, the treatment outcome of curative resection combined with standard chemotherapy was evaluated in patients with liver and̸or lung metastatic CRC. Furthermore, the clinical predictive factors determining the benefits of curative resection for synchronous metastases were identified. (Table I ). All the patients had histologically confirmed CRC with distant metastasis and underwent curative resection for the primary and metastatic lesions. The surgical specimens were fixed in formalin, processed through graded ethanols and embedded in paraffin blocks. The histological sections were stained with hematoxylin and eosin and elastica-van Gieson's stain and the degree of histological differentiation, lymphatic invasion and venous invasion were assessed. Data on patient age and gender, primary tumour site (rectum or colon), distant metastatic site (liver and/or lung), pathological stage (histological grade, tumour invasiveness, lymph node metastases, lymphatic invasion and venous invasion) and perioperative chemotherapy were retrieved from patient medical records and retrospectively evaluated.
Materials and methods

Patient characteristics.
Preoperative evaluation. Preoperatively, the extent of tumour spread was determined by using modalities such as X-ray, computed tomography (CT), magnetic resonance imaging and/or positron emission tomography (PET). The intraoperative findings contributed to the determination of metastatic tumour spread. Following surgery, all the patients underwent follow-up blood tests measuring the serum carcinoembryonic antigen (CEA) levels and imaging examinations, such as abdominal ultrasonography, CT, chest X-ray and̸or PET every 3-6 months. In this study, the time-to-recurrence after the first synchronous curative resection for primary and metastatic lesions was also evaluated during the postoperative follow-up and is referred to as 'recurrence interval'.
Adjuvant therapy. Postoperatively, a proportion of the patients received chemotherapy following provision of written informed consent. The adjuvant therapies were administered according to the the guidelines of the Japanese Society for Cancer of the Colon and Rectum (8) Kaplan-Meier survival curves were plotted and compared with the generalized log-rank test. Univariate and multivariate analyses were performed using a Cox regression model for overall survival (OS) and disease-free survival (DFS) following final curative resection, to identify independent factors. Two-sided P-values of <0.05 were considered to indicate statistically significant differences. All the tests were analyzed using JMP software, version 11.0 (SAS Institute, Cary, NC, USA).
This study was designed in accordance with the Institutional Ethical Guidelines and received approval from the Ethics Committee of the Osaka Medical Center for Cancer and Cardiovascular Diseases. 
Results
Patient characteristics. The patient characteristics are summarized in Table I . The median patient age was 61 years (range, 20-81 years) and 61 patients (59.2%) were male. The primary tumours were located in the rectum (36 patients, 35.0%), or the colon (67 patients, 65.0%). The most common site of metastases at presentation was the liver (90 patients, 87.3%), followed by the lung (20 patients, 19.4%). The median number of liver or lung metastatic sites was 2 (range, 1-7) and 1 (range, 1-3), respectively.
Survival analysis. The median OS in the entire study population was 4.60 years. The cohort of 103 patients underwent curative resection of primary and metastatic lesions. Curative resection of the liver or lung was performed in 90 and 20 patients, respectively, whereas liver and lung resections were concurrently performed in 7 patients. The median OS was 20.7 months in this population (Fig. 1) . Following curative resection, 25 patients (24.2%) had no recurrence [median DFS, 5.69 years (range, 1.20-21.73 years)], whereas 14 patients (13.5%) received more than one re-resection for disease recurrence and survived without any further recurrence thereafter [median DFS, 5.53 years (range, 2.30-11.89 years)]. The DFS curves of liver, lung and synchronous liver and lung metastatic CRC are plotted in Fig. 2 .
Treatment outcome. Following curative resection, the patients exhibited several recurrences such as in the liver, lung, bone, brain and distant lymph nodes (Table II) . In cases with liver or lung metastatic CRC, 17 and 8 patients, respectively, underwent curative resection of primary and metastatic lesions without any recurrence. However, in cases with synchronous liver and lung metastatic CRC, all the patients developed re-recurrence following curative resection and the median DFS of this population was 5.46 months. Chemotherapy. Of the 103 patients, 81 (78.6%) received adjuvant chemotherapy following curative resection. Oxaliplatin and irinotecan were used in 22 (27.1%) and 15 patients (18.5%), respectively. 5-FU, capecitabine or UFT were administered to 77 patients (74.7%). Finally, 8 patients (7.7%) received bevacizumab. In our study, the selection of chemotherapy was not found to be significantly associated with patient outcome (Table III) .
Factors associated with DFS. The univariate and multivariate analyses of factors associated with DFS are presented in Table IV . In the univariate analysis, tumour invasion [hazard Table III . Univariate analysis for overall survival with chemotherapy following curative resection (Cox proportional hazards regression model). Factors associated with OS. The univariate and multivariate analyses of factors associated with OS are presented in Table V . In the univariate analysis, primary CRC location (HR=3.09, 95% CI: 1.44-6.03, P=0.005), tumour invasion (HR=1.56, 95% CI: 1.01-2.38, P=0.045), synchronous liver and lung metastases (HR=2.99, 95% CI: 1.23-6.18, P=0.018) and recurrence interval after the first curative resection (HR=2.69, 95% CI: 1.78-4.11, P<0.001) were significantly correlated with OS. In the multivariate analysis, primary CRC location (HR=4.45, 95% CI: 1.91-9.54, P=0.001), tumour invasion (HR=5.99, 95% CI: 3.06-12.34, P<0.001), synchronous liver and lung metastases (HR=4.03, 95% CI: 1.44-9.77, P=0.010) and recurrence interval after the first curative resection (HR=7.95, 95% CI: 3.97-17.14, P<0.001) were found to be independent predictors of OS.
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Discussion
CRC patients with isolated liver or lung metastasis may achieve long-term survival with concurrent curative resection of the primary and metastatic lesions.
It may be useful to determine the necessity of intensive follow-up and selective adjuvant therapy for CRC patients by predicting recurrence and metastases following curative surgical resection (10, 11) . In the present study, the clinicopathological analysis revealed that CRC patients with T4a-4b disease had a poorer prognosis regarding DFS and OS compared to those with T3 disease. Additionally, CRC with synchronous liver and lung metastases was associated with a poorer prognosis compared to CRC with isolated liver or lung metastasis. The data indicated that tumour invasiveness and Table V . Univariate and multivariate analyses of factors associated with OS (Cox proportional hazards regression model).
Univariate analysis
Multivariate analysis metastatic status (liver and lung) are independent prognostic factors. As regards OS, primary cancer location at the lower rectum and anal region was associated with worse prognosis. It was previously reported that rectal cancer exhibits early recurrence, resulting in poor prognosis (12) . Unlike previous studies indicating several prognostic factors, such as lymph node metastasis and vascular invasion, these factors were not found to be prognostically significant, as all the patients in our study had stage IV disease (13, 14) . In the clinical setting, it must be decided whether re-resection should be selected for recurrence following curative surgical resection for metastatic CRC. In the present study, we also evaluated the recurrence interval during the follow-up period after the first curative surgical resection for metastatic CRC. Our results indicated that a recurrence interval of <1 year was associated with a poorer prognosis in terms of DFS and OS after the final curative resection. Our results suggested that combination therapy, namely palliative surgical resection and chemotherapy, may be an option for recurrent cases that appear within 1 year after the first curative resection (3). In CRC therapy, it is essential to prevent metachronous metastasis. Several adjuvant chemotherapies may be beneficial for advanced metastatic CRC (10, 15) . In such cases, predictive markers of metastasis are crucial, regardless of the traditional TNM classification, and may contribute to the diagnosis and treatment of metachronous distant metastases.
In the present study, the combination of adjuvant chemotherapies did not result in statistically significant differences in patient outcome. This may be due to the fact that the reviewed data were collected over the past 20 years, within which time the strategy of the adjuvant treatment has changed. Adjuvant chemotherapy for CRC has been the treatment of choice in highly suspicious metachronous metastatic cases (16, 17) . Improving treatments, such as postoperative chemotherapy, combination therapy with chemotherapy following surgical resection, or palliative surgical resection with chemotherapy for metastatic CRC, may contribute to improving patient outcome (3, 10, (15) (16) (17) .
In summary, surgical resection may be a potentially curative option for selected CRC patients with liver or lung metastasis. If the metastases are diagnosed as potentially resectable and the patient's performance status is satisfactory, surgical resection of the primary as well as the metastatic lesions may be a viable treatment option. Following surgical resection, tumour invasiveness should be considered. With the combination of surgery and improved chemotherapy, longer-term survival may be achieved.
